Sophia Humphreys, PharmD, explains that expanding biosimilars into new therapeutic areas faces hesitance due to maintenance therapies, emphasizing the importance of education, and highlights factors ...
Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...
The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more ...
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward ...
The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...
During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...
Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback